key: cord-0993936-j535npzz
authors: Mouhayar, Elie N.; Hammond, Danielle; Lopez-Mattei, Juan; Banchs, Jose; Konopleva, Marina; Pemmaraju, Naveen
title: Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome
date: 2021-12-21
journal: JACC CardioOncol
DOI: 10.1016/j.jaccao.2021.09.009
sha: 85f5579c2d7e621084fb2b7d2c9a99d66f48170c
doc_id: 993936
cord_uid: j535npzz

[Figure: see text]

Per detailed history, he had no viral prodrome in the preceding weeks. The patient's electrocardiogram at admission showed new inverted T waves in inferolateral leads and newly elevated cardiac biomarkers (high-sensitivity troponin T 118 ng/L [normal #18 ng/L] and N-terminal pro-B-type natriuretic peptide 3,498 pg/mL [normal #125 pg/mL]). His serum albumin level had decreased from a baseline of 4.8 to 3.2 mg/dL despite the prior prophylactic albumin infusions. His CBC demonstrated a leukocytosis of 33.2 K/mL, hemoconcentration (hematocrit 52%), and thrombocytopenia (platelet count 40,000/mL). Hyponatremia (sodium 132 mEq/L) was noted with normal renal function. His liver transaminase levels remained moderately elevated (alanine transaminase 179 U/L and aspartate aminotransferase 158 U/L). A nasopharyngeal PCR swab for common respiratory viral pathogens (including SARS-CoV-2) was negative, as were his blood and urine cultures. A repeat transthoracic echocardiogram was obtained, and compared with his baseline study from a few weeks before, there were no new segmental wall motion abnormalities nor changes in LV systolic function. However, there was an approximate 3-fold increase in the LV apical wall thickness and associated impaired myocardial relaxation with decreased mitral annular tissue Doppler velocities. The predominant appearance of the LV was very similar to apical hypertrophic cardiomyopathy. There was increased right ventricular (RV) free wall thickness as well. His peak LV global longitudinal strain had changed from a normal value of À21.3% to À15.5% (<À18% abnormal). Initial cardiovascular cardiac magnetic resonance (CMR) (1.5-T) showed normal cardiac chamber sizes with concentric LV and RV hypertrophy, normal biventricular systolic function (LVEF 63%, RVEF 50%), and the absence of regional wall motion abnormalities. The pericardium was of normal thickness with a small circumferential pericardial effusion. There was myocardial patchy late gadolinium enhancement noted with an increased T 2 value of 68 milliseconds (normal <55 milliseconds) and increased LV mass index of 89.69 g/m 2 (normal <75 g/m 2 ) ( Figure 1A) . The native T 1 value measured in the midseptum was 1,462 milliseconds (normal ¼ 1,034 AE 39 milliseconds) with an extracellular volume fraction (ECV) of 28% (normal ¼ 25.3% AE 3.5%).

In light of the cardiac biomarker injury pattern and echocardiographic/CMR findings, his presentation was suspected to be a manifestation of CLS with secondary myocardial edema. He was initially treated with supplemental oxygen by nasal cannula, a furosemide infusion at 3 mg/h, methylprednisolone 125 mg IV every 6 hours, and 25 g of albumin 25% every 12 hours with a target daily negative fluid balance of 1-2 L and target trough serum albumin >3.2 g/dL. An endomyocardial biopsy was considered, but ultimately not performed because of rapid clinical improvement. His fatigue, dyspnea, hypoxia, and peripheral edema improved over a 5-day period. A repeat limited transthoracic echocardiogram 3 days after admission showed an LVEF of 70%, and persistent wall thickening predominantly involving the apical segments. He was discharged home 7 days after admission on a tapered schedule of oral prednisone and diuretic. He was followed closely in the outpatient setting with progressive normalization of his cardiac biomarkers over 8 weeks. A repeat CMR 1 month after admission showed resolution of the previous delayed hyperenhancement with normalization of both T 2 maps (49 milliseconds) and LV mass index (74 g/m 2 ) values ( Figure 1B) . The native T 1 value and the ECV decreased to 1,207 milliseconds and 21%, respectively. A repeat echocardiogram 3 months after admission demonstrated complete resolution of the previous biventricular thickness changes and pericardial effusion with normalization of tissue Doppler parameters and LV global longitudinal strain.

The patient's BPDCN-directed therapy was resumed 1 month later with a reduced dose of tagraxofusp (9 mg/kg  3 days) and prophylactic daily diuretic and albumin infusions. He tolerated all 5 subsequent cycles well and proceeded to an allogeneic stem cell transplant after which he remains in complete remission over 1.5 years later.

Capillary leak syndrome (CLS) is the shared biological endpoint of vascular endothelial hyperpermeability resulting from a variety of inciting etiologies. Extravasation of plasma and proteins into the interstitial space underlies the clinical triad of hypoalbuminemia, hemoconcentration, and hypotension that, if untreated, can lead to distributive shock. The eponymous idiopathic form of CLS is known as Clarkson disease (1). CLS can also be secondary to autoimmune diseases, viral infections, and snakebites, but the most common secondary and subsequent normalization of T 2 maps, LV index, and ECV on CMR further reinforces this diagnosis.

The patient had no demonstrable alternative differential. Although the possibility of undiagnosed acute myocarditis cannot be eliminated, the collective clinical presentation and cardiac imaging findings are more likely to be CLS-mediated myocardial injury.

This case illustrates the importance of recognizing myocardial edema as a rare but serious manifestation of CLS, in this case tagraxofusp-induced. Early noninvasive cardiac imaging is critical to diagnosing secondary myocardial edema and excluding alternative ischemic, inflammatory, infiltrative cardiomyopathies. The dynamic improvement this patient's baseline echocardiographic and CMR abnormalities emphasize the potentially reversible nature of CLS-related myocardial injury.

Tagraxofusp is an intravenously administered CD123-targeted diphtheria toxin conjugate drug used in the treatment of rare hematological malignancies. We present a case of myocardial involvement in a tagraxofuspinduced capillary leak syndrome (CLS). This case highlights the importance of using longitudinal noninvasive cardiac imaging to recognize this pattern of reversible cardiac injury as well as the early application of measures to reverse the fluid retention and oncotic effects of CLS and the successful rechallenge of the CD123directed agent in subsequent cycles after the occurrence of CLS.

Dr Konopleva has served as a consultant for and received research funding from Stemline Therapeutics. Dr Pemmaraju has received honoraria and research funding from Stemline Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. emouhayar@mdanderson.org. Twitter: @EMouhayar, @DanielleHammo20, @onco_cardiology, @doctorpemm.

Idiopathic systemic capillary leak syndrome (Clarkson disease)

Characterizing drug-induced capillary leak syndromes using the World Health Organization Vig-iBase

Myocardial involvement in systemic capillary leak syndrome: first demonstration by pathologic findings

Increased myocardial extracellular volume in active idiopathic systemic capillary leak syndrome

Amoura Z, for the EureClark Study Group. Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe episodes

Myocardial oedema in an 8-year-old Chinese boy with Idiopathic systemic capillary leak syndrome

Myocardial edema in paroxysmal permeability disorders: The paradigm of Clarkson's disease

Clinical and pathological findings of a fatal systemic capillary leak syndrome (Clarkson disease): a case report

Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm

Center for Drug Evaluation and Research. Application number 761116Orig1s000. Summary review

KEY WORDS blastic plasmacytoid dendritic cell neoplasm, capillary leak syndrome, myocardial edema, tagraxofusp